Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology

Open Access 05-04-2024 | Pancreatoduodenostomy | Pancreatic Tumors

Long-Term Oncologic Outcome following Duodenum-Preserving Pancreatic Head Resection for Benign Tumors, Cystic Neoplasms, and Neuroendocrine Tumors: Systematic Review and Meta-analysis

Authors: Hans G. Beger, MD, Benjamin Mayer, PhD, Bertram Poch, MD, PD

Published in: Annals of Surgical Oncology

Login to get access

Abstract

Background

Pancreatoduodenectomy (PD) has a considerable surgical risk for complications and late metabolic morbidity. Parenchyma-sparing resection of benign tumors has the potential to cure patients associated with reduced procedure-related short- and long-term complications.

Materials and Methods

Pubmed, Embase, and Cochrane libraries were searched for studies reporting surgery-related complications following PD and duodenum-preserving total (DPPHRt) or partial (DPPHRp) pancreatic head resection for benign tumors. A total of 38 cohort studies that included data from 1262 patients were analyzed. In total, 729 patients underwent DPPHR and 533 PD.

Results

Concordance between preoperative diagnosis of benign tumors and final histopathology was 90.57% for DPPHR. Cystic and neuroendocrine neoplasms (PNETs) and periampullary tumors (PATs) were observed in 497, 89, and 31 patients, respectively. In total, 34 of 161 (21.1%) patients with intraepithelial papillar mucinous neoplasm exhibited severe dysplasia in the final histopathology. The meta-analysis, when comparing DPPHRt and PD, revealed in-hospital mortality of 1/362 (0.26%) and 8/547 (1.46%) patients, respectively [OR 0.48 (95% CI 0.15–1.58); p = 0.21], and frequency of reoperation of 3.26 % and 6.75%, respectively [OR 0.52 (95% CI 0.28–0.96); p = 0.04]. After a follow-up of 45.8 ± 26.6 months, 14/340 patients with intraductal papillary mucinous neoplasms/mucinous cystic neoplasms (IPMN/MCN, 4.11%) and 2/89 patients with PNET (2.24%) exhibited tumor recurrence. Local recurrence at the resection margin and reoccurrence of tumor growth in the remnant pancreas was comparable after DPPHR or PD [OR 0.94 (95% CI 0.178–5.34); p = 0.96].

Conclusions

DPPHR for benign, premalignant neoplasms provides a cure for patients with low risk of tumor recurrence and significantly fewer early surgery-related complications compared with PD. DPPHR has the potential to replace PD for benign, premalignant cystic and neuroendocrine neoplasms.
Appendix
Available only for authorised users
Literature
1.
Kromrey ML, Bülow R, Hübner J, et al. Prospective study on the incidence, prevalence and 5-year pancreatic-related mortality of pancreatic cysts in a population-based study. Gut. 2018;67:138–45.PubMedCrossRef
2.
Sahora K, Mino-Kenudson M, Brugge W, Thayer SP, Ferrone CR, Sahani D, et al. Branch duct intraductal papillary mucinous neoplasms: does cyst size change the tip of the scale? A critical analysis of the revised international consensus guidelines in a large single-institutional series. Ann Surg. 2013;258:466–75.PubMedCrossRef
3.
Sahora K, Fernández-del Castillo C, Dong F, Marchegiani G, Thayer SP, Ferrone CR, et al. Not all mixed-type intraductal papillary mucinous neoplasms behave like main-duct lesions: implications of minimal involvement of the main pancreatic duct. Surgery. 2014;156:611–21.PubMedCrossRef
4.
Tanaka M, Fernández-del Castillo C, Adsay V, Chari S, Falconi M, Jang JY, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology. 2012;12:183–97.PubMedCrossRef
5.
Wang P, Wei J, Wu J, et al. Diagnosis and treatment of solid-pseudopapillary tumors of the pancreas: a single institution experience with 97 cases. Pancreatology. 2018;18:415–9.PubMedCrossRef
6.
Halfdanarson TR, Rubin J, Farnell MB, Grant CS, Petersen GM. Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors. Endocr Rel Can. 2008;2008(15):409–27.CrossRef
7.
Mintziras I, Keck T, Werner J, Fichtner-Feigl S, Wittel U, Senninger N, et al. Implementation of current ENETS guidelines for surgery of small (≤ 2 cm) pancreatic neuroendocrine neoplasms in the German surgical community: an analysis of the prospective DGAV StuDoQ| Pancreas registry. World J Surg. 2019;43:175–82.PubMedCrossRef
8.
Barnes SA, Lillemoe KD, Kaufman HS, et al. Pancreaticoduodenectomy for benign disease. Am J Surgery. 1996;171:131–6.CrossRef
9.
Newhook TE, LaPar DJ, Lindberg JM, Bauer TW, Adams RB, Zaydfudim VM. Morbidity and mortality of pancreaticoduodenectomy for benign and premalignant pancreatic neoplasms. J Gastrointest Surg. 2015;19:1072–7.PubMedCrossRef
10.
Mavroeidis VK, Russell TB, Clark J, et al. 2023 Pancreatoduodenectomy for suspected malignancy: nonmalignant histology confers increased risk of serious morbidity. Ann R Coll Surg Engl. 2023;105:446–54.PubMedCrossRef
11.
Nimptsch U, Krautz C, Weber GF, Mansky T, Grützmann R. Nationwide in-hospital mortality following pancreatic surgery in Germany is higher than anticipated. Ann Surg. 2016;264:1082–90.PubMedCrossRef
12.
Liu Z, Peneva IS, Evison F, et al. Ninety day mortality following pancreatoduodenectomy in England: has the optimum centre volume been identified? HPB. 2018;20:1012–20.PubMedCrossRef
13.
Reid-Lombardo KM, Thomsen K, Harmsen WS, Farnell MB. Long-term anastomotic complications after pancreaticoduodenectomy for benign diseases. J Gastrointest Surg. 2007;11:1704–11.PubMedCrossRef
14.
Narayanan S, Martin AN, Turrentine FE, Bauer TW, Adams RB, Zaydfudim VM. Mortality after pancreaticoduodenectomy: assessing early and late causes of patient death. J Surg Res. 2018;231:304–8.PubMedPubMedCentralCrossRef
15.
Beger HG, Mayer B, Poch B. Long-term metabolic morbidity and steatohepatosis following standard pancreatic resections and parenchyma-sparing, local extirpations for benign tumor - A systematic review and meta-analysis. Ann Surg. 2022;275:54–66.PubMedCrossRef
16.
Thomas AS, Huang Y, Kwon W, et al. Prevalence and risk factors for pancreatic insufficiency after partial pancreatectomy. J Gastrointest Surg. 2022;26:1425–35.PubMedCrossRef
17.
18.
Beger HG, Siech M, Poch B, Mayer B, Schoenberg MH. Limited surgery for benign tumors of the pancreas: a systematic review. World J Surg. 2015;39:1557–66.PubMedCrossRef
19.
Iacono C, Verlato G, Ruzzenente A, et al. Systematic review of central pancreatectomy and meta-analysis of central versus distal pancreatectomy. Br J Surg. 2013;100:873–85.PubMedCrossRef
20.
Fujii T, Kanda M, Kodera Y, et al. Comparison of pancreatic head resection with segmental duodenectomy and pylorus-preserving pancreatoduodenectomy for benign and low-grade malignant neoplasms of the pancreatic head. Pancreas. 2011;40:1258–63.PubMedCrossRef
21.
Asano T, Nakamura T, Noji T, et al. Outcomes of limited resection for patients with intraductal papillary mucinous neoplasm of the pancreas: a single-center experience. Pancreatology. 2020;20:1399–405.PubMedCrossRef
22.
Beger HG, Mayer B, Poch B. Resection of the duodenum causes long-term endocrine and exocrine dysfunction after Whipple procedure for benign tumors-Results of a systematic review and meta-analysis. HPB. 2020;22:809–20.PubMedCrossRef
23.
Moher D, Liberati L, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analysis: the PRISMA statement. Ann Intern Med. 2009;151:265–9.
24.
25.
26.
Habib JR, Kinny-Köster B, Amini N, et al. Predictors, patterns, and timing of recurrence provide insight into the disease biology of invasive carcinomas arising in association with intraductal papillary mucinous neoplasms. J Gastrointest Surg. 2022;26:2311–20.PubMedCrossRef
27.
Fletcher RH, Flechter SW, Flechter GS. Clinical epidemiology: the essentials. Philadelphia: Lipponcott Williams & Wilkins; 2019.
28.
Lu C, Xu B, Mou Y, Zhou Y, Jin W, Xia T, et al. Laparoscopic duodenum–preserving pancreatic head resection with real-time indocyanine green guidance of different dosage and timing: enhanced safety with visualized biliary duct and its long-term metabolic morbidity. Langenbeck’s Arch Surg. 2022;407:2823–32.CrossRef
29.
Zhou M, Xu S, Chao D, Wang M, Zhu F, Peng F, et al. Intracapsular approach used in laparoscopic duodenum-preserving total pancreatic head resection for pancreatic head benign or low-grade malignant tumors. Langenbeck’s Arch Surg. 2022;407:3851–8.CrossRef
30.
Hong D, Cheng J, Wu W, Liu X, Zheng X. How to perform total laparoscopic duodenum-preserving pancreatic head resection safely and efficiently with innovative techniques. Ann Surg Oncol. 2021;28:3209–16.PubMedCrossRef
31.
Lin X, Zhang J, Xie F, Hu Z, He Q, Long Q, et al. Laparoscopic duodenum-preserving total pancreatic head resection in benign and low-grade malignant tumors. Frontiers in Surg. 2013;17(3):126.
32.
Cai Y, Zheng Z, Gao P, Li Y, Peng B. Laparoscopic duodenum-preserving total pancreatic head resection using real-time indocyanine green fluorescence imaging. Surg Endosc. 2021;35:1355–61.PubMedCrossRef
33.
Cao J, Li GL, Wei JX, et al. Laparoscopic duodenum-preserving total pancreatic head resection: a novel surgical approach for benign or low-grade malignant tumors. Surg Endosc. 2019;33:633–8.PubMedCrossRef
34.
Snajdauf J, Rygl M, Petru O, et al. Indications and outcomes of duodenum-preserving resection of the pancreatic head in children. Pediatr Surg Int. 2019;35:449–55.PubMedCrossRef
35.
Milanetto AC, Lico V, Allagio R, Pedrazzoli S, Pasquali C. Duodenum-preserving pancreatic head resection for treatment of neuroendocrine pancreatic tumors of the head of the pancreas. Pancreatology. 2016;16:S65–6.CrossRef
36.
Thomas E, Matsuoka L, Alexopoulos S, Selby R, Parekh D. Laparoscopic hand-assisted parenchymal-sparing resections for presumed side-branch intraductal papillary mucinous neoplasms. J Laparoend Adv Surg Tech. 2015;25:668–71.CrossRef
37.
Kozlov IA, Smirnov AV, Chzhao AV. Duodenum-preserving pancreatic head resection and resection of the head of the pancreas combined with segmental duodenectomy. HPB. 2014;16(Suppl. 2):594–5.
38.
Suzuki R, Hatori T, Suzuki S, et al. The treatment strategy of non-functioning pancreatic neuroendocrine tumor. Pancreatology. 2013;4:S74–5.CrossRef
39.
Tsuchikawa T, Hirano S, Tanaka E, et al. Modified duodenum-preserving pancreas head resection for low-grade malignant lesion in the pancreatic head. Pancreatology. 2013;13:170–4.PubMedCrossRef
40.
Nakagohri T, Kinoshita T, Konishi M, et al. Inferior head resection of the pancreas for intraductal papillary mucinous neoplasms. J Hepatobiliary Pancreat Sci. 2010;17:798–802.PubMedCrossRef
41.
Beger HG, Gansauge F, Siech M, Schwarz M, Poch B. Duodenum-preserving total pancreatic head resection for cystic neoplastic lesions in the head of the pancreas. J Hepatobiliary Pancreat Surg. 2008;15:149–56.PubMedCrossRef
42.
Xiong JX, Wang CY, Tao J, Zhang SH. Indication and choice of operation technique for duodenum-preserving resection of pancreatic head: 22 cases reports. Zhonghua wai ke za zhi [Chin J Surg]. 2007;45:24–6.PubMed
43.
Fernández-Cruz L, Olvera C, López-Boado MA, Bollo J, Romero J, Comas J. Organ-preserving resection of the pancreaticoduodenal region in the treatment of intraductal papillary mucinous tumors. Cir Esp. 2006;80:295–300.PubMedCrossRef
44.
Ito K, Takada T. Duodenum preservation in pancreatic head resection to maintain pancreatic exocrine function (determined by pancreatic function diagnostant test and cholecystokinin secretion). J Hepatobiliary Pancreat Surg. 2005;12:123–8.PubMedCrossRef
45.
Murakami Y, Uemura K, Yokoyama Y, et al. Pancreatic head resection with segmental duodenectomy for intraductal papillary mucinous tumors of the pancreas. J Gastrointest Surg. 2004;8:713–9.PubMedCrossRef
46.
Hirano S, Kondo S, Ambo Y, et al. Outcome of duodenum-preserving resection of the head of the pancreas for intraductal papillary-mucinous neoplasm. Dig Surg. 2004;21:242–5.PubMedCrossRef
47.
Takada T, Yasuda H, Amano H, Yoshida M. A duodenum-preserving and bile duct-preserving total pancreatic head resection with associated pancreatic duct-to-duct anastomosis. J Gastrointest Surg. 2004;8:220–4.PubMedCrossRef
48.
Isaji S, Kawarada Y. Pancreatic head resection with second-portion duodenectomy for benign lesions, low-grade malignancies, and early stage carcinomas involving the pancreatic head region. Am J Surg. 2001;181:172–6.PubMedCrossRef
49.
Naritomi G, Tanaka M, Matsunaga H, Yokohata K, Ogawa Y, Chijiiwa K, et al. Pancreatic head resection with and without preservation of the duodenum: different postoperative gastric motility. Surgery. 1996;120:831–7.PubMedCrossRef
50.
Imaizumi T, Hanyu F, Suzuki M, Nakasako T, Harada N, Hatori T. Clinical experience with duodenum-preserving total resection of the head of the pancreas with pancreaticocholedochoduodenostomy. J Hepatobiliary Pancreat Surg. 1995;2:38–44.CrossRef
51.
Harada N. Digestive functions and secretion of gastrointestinal hormones after duodenum-preserving pancreas head resection. Jpn J Gastroenterol Surg. 1994;27:781–8.CrossRef
52.
Liu W, Peng B. Laparoscopic duodenum-preserving total pancreatic head resection versus laparoscopic pancreaticoduodenectomy for pancreatic-head intraductal papillary mucinous neoplasm. Asian J Surg. 2022;46(6):2293–8.PubMedCrossRef
53.
Sun YH, Ding N, Cheng K, Lin H, Xu JQ, Chen QL. Comparative analysis of duodenum-preserving pancreatic head resection and pancreaticoduodenectomy. Chin Med J. 2020;133:2112–3.PubMedPubMedCentralCrossRef
54.
Chen X, Chen W, Zhang Y, An Y, Zhang X. Short-term outcomes of laparoscopic duodenum-preserving total pancreatic head resection compared with laparoscopic pancreaticoduodenectomy for the management of pancreatic-head benign or low-grade malignant lesions. Med Sci Monitor. 2020;26:e927248–51.CrossRef
55.
Qin H, Yang S, Yang, et al. Duodenum-preserving pancreas head resection in the treatment of pediatric benign and low-grade malignant pancreatic tumors. HPB. 2020;22:306–11.PubMedCrossRef
56.
Jiang Y, Jin JB, Zhan Q, et al. Robot-assisted duodenum-preserving pancreatic head resection with pancreaticogastrostomy for benign or premalignant pancreatic head lesions: a single-centre experience. Int J Med Robot. 2018;14:e1903.PubMedCrossRef
57.
Li Y, Wu W, Zhang T, Liao Q, Zhao Y, Dai M. Comparison of long-term benefits of organ-preserving pancreatectomy techniques for benign or low-grade malignant tumors at the pancreatic head. Medicine (Baltimore). 2017;96(51):e9420.PubMedCrossRef
58.
Perinel J, Adham M. Short-and long-term outcomes of pancreatectomy with or without biliary tract and duodenum preservation for benign and borderline neoplasms. Dig Surg. 2014;31:233–41.PubMedCrossRef
59.
Liu JZ, Huang XY, Wang HC, Zhen Q. Duodenum-preserving pancreatic head resection versus pancreaticoduodenectomy for benign pancreatic neoplasms. HPB. 2013;15(Suppl. 2):540.
60.
Gong DJ, Zhang JM, Mao GJ, et al. Duodenum-preserving pancreatic head resection vs. pancreatoduodenectomy for benign lesions and low-grade malignancies of the pancreatic head. Hepatogastroenterology. 2013;60:19–22.PubMed
61.
Pedrazzoli S, Canton SA, Sperti C. Duodenum-preserving versus pylorus-preserving pancreatic head resection for benign and premalignant lesions. J Hepatobiliary Pancreat Sci. 2011;18:94–102.PubMedCrossRef
62.
Busquets J, Fabregat J, Borobia FG, et al. Organ-preserving surgery for benign lesions and low-grade malignancies of the pancreatic head: a matched case-control study. Surg Today. 2010;40:125–31.PubMedCrossRef
63.
Horiguchi A, Miyakawa S, Ishihara S, et al. Surgical design and outcome of duodenum-preserving pancreatic head resection for benign or low-grade malignant tumors. J Hepatobiliary Pancreat Sci. 2010;17:792–7.PubMedCrossRef
64.
Lee SE, Jang JY, Hwang DW, Lee KU, Kim SW. Clinical efficacy of organ-preserving pancreatectomy for benign or low-grade malignant potential lesion. J Korean Med Sci. 2010;25(1):97–103.PubMedCrossRef
65.
66.
Tanaka M, Fernández-del Castillo C, Kamisawa T, Jang JY, Levy P, Ohtsuka T, et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology. 2017;17:738–53.PubMedCrossRef
67.
European Study Group on Cystic Tumours of the pancreas. European evidence-based guidelines on pancreatic cystic neoplasms. Gut 2018;67:789-804.
68.
Vege SS, Ziring B, Jain R, Moayyedi P, Adams MA, Dorn SD, et al. American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology. 2015;148:819–22.PubMedCrossRef
69.
Vaalavuo Y, Siiki A, Antila A, Rinta-Kiikka I, Sand J, Laukkarinen J. The European evidence-based guidelines on pancreatic cystic neoplasms (PCN) in clinical practice: the development of relative and absolute indications for surgery during prospective IPMN surveillance. Pancreatology. 2020;20:1393–8.PubMedCrossRef
70.
Maker AV, Carrara S, Jamieson NB, et al. Cyst fluid biomarkers for intraductal papillary mucinous neoplasms of the pancreas: a critical review from the international expert meeting on pancreatic branch-duct-intraductal papillary mucinous neoplasms. J Am Coll Surg. 2015;220:243–53.PubMedCrossRef
71.
Tjaden C, Sandini M, Mihaljevic AL, et al. Risk of the watch-and-wait concept in surgical treatment of intraductal papillary mucinous neoplasm. JAMA Surg. 2021;156:818–25.PubMedPubMedCentralCrossRef
72.
Salvia R, Burelli A, Perri G, Marchegiani G. State-of-the-art surgical treatment of IPMNs. Langenbeck’s Arch Surg. 2021;406:2633–43.CrossRef
73.
Asano Y, Kato H, Arakawa S, Ito M, Nagakawa T, Nakao A, et al. Clinical outcomes of organ-preserving pancreatectomy for benign or low-grade malignant pancreatic tumors: a multicenter nationwide survey in Japan. J Hepatobiliary Pancreat Sci. 2022;29(8):898–910.PubMedCrossRef
74.
Hirono S, Shimizu Y, Ohtsuka T, et al. Recurrence patterns after surgical resection of intraductal papillary mucinous neoplasm (IPMN) of the pancreas; a multicenter, retrospective study of 1074 IPMN patients by the Japan Pancreas Society. J Gastroenterol. 2020;55:86–99.PubMedCrossRef
75.
Remotti HE, Winner M, Saif MW. Intraductal papillary mucinous neoplasms of the pancreas: clinical surveillance and malignant progression, multifocality and implications of a field-defect. JOP. 2012;13(2):135–8.PubMed
76.
Fischer CG, Guthrie VB, Braxton AM, Zheng L, Wang P, Song Q, et al. Intraductal papillary mucinous neoplasms arise from multiple independent clones, each with distinct mutations. Gastroenterology. 2019;157:1123–37.PubMedCrossRef
77.
Koh YX, Zheng HL, Chok AY, Tan CS, Wyone W, Lim TK, et al. Systematic review and meta-analysis of the spectrum and outcomes of different histologic subtypes of noninvasive and invasive intraductal papillary mucinous neoplasms. Surgery. 2015;157(3):496.PubMedCrossRef
78.
Noë M, Niknafs N, Fischer CG, Hackeng WM, Beleva Guthrie V, Hosoda W, et al. Genomic characterization of malignant progression in neoplastic pancreatic cysts. Nature Comm. 2020;11:4085.CrossRef
79.
Kang MJ, Jang JY, Lee KB, Chang YR, Kwon W, Kim SW. Long-term prospective cohort study of patients undergoing pancreatectomy for intraductal papillary mucinous neoplasm of the pancreas: implications for postoperative surveillance. Ann Surg. 2014;260(2):356–63.PubMedCrossRef
80.
Amini N, Habib JR, Blair A, Rezaee N, Kinny-Köster B, Cameron JL, et al. Invasive and noninvasive progression after resection of noninvasive intraductal papillary mucinous neoplasms. Ann Surg. 2022;276(2):370–7.PubMedCrossRef
81.
Miller JR, Meyer JE, Waters JA, Al-Haddad M, DeWitt J, Sherman S, et al. Outcome of the pancreatic remnant following segmental pancreatectomy for non-invasive intraductal papillary mucinous neoplasm. HPB. 2011;13:759–66.PubMedPubMedCentralCrossRef
82.
Rezaee N, Barbon C, Zaki A, He J, Salman B, Hruban RH, et al. Intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia is a risk factor for the subsequent development of pancreatic ductal adenocarcinoma. HPB. 2016;18(3):236–46.PubMedCrossRef
83.
Falconi M, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M, et al. ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology. 2016;103(2):153–71.PubMedCrossRef
84.
Andreasi V, Muffatti F, Guarneri G, Falconi M, Partelli S. Surgical principles in the management of pancreatic neuroendocrine neoplasms. Curr Treat Options Oncol. 2020;21:1–14.CrossRef
85.
Finkelstein P, Sharma R, Picado O, Gadde R, Stuart H, Ripat C, et al. Pancreatic neuroendocrine tumors (panNETs): analysis of overall survival of nonsurgical management versus surgical resection. J Gastroint Surg. 2017;21:855–66.CrossRef
86.
Beane JD, Borrebach JD, Billderback A, Onuma AE, Adam MA, Zureikat AH, et al. Small pancreatic neuroendocrine tumors: resect or enucleate? Am J Surg. 2021;222(1):29–34.PubMedCrossRef
87.
Chivukula SV, Tierney JF, Hertl M, Poirier J, Keutgen XM. Operative resection in early stage pancreatic neuroendocrine tumors in the United States: are we over-or undertreating patients? Surgery. 2020;167:180–6.PubMedCrossRef
88.
Sallinen VJ, Le Large TY, Tieftrunk E, et al. & Pancreas 2000 research group. Prognosis of sporadic resected small (≤ 2 cm) nonfunctional pancreatic neuroendocrine tumors–a multi-institutional study. HPB 2018;20:251-259.
89.
Duconseil P, Marchese U, Ewald J, et al. A pancreatic zone at higher risk of fistula after enucleation. World J Surg Oncol. 2018;16:1–9.CrossRef
90.
Heeger K, Falconi M, Partelli S, Waldmann J, Crippa S, Fendrich V, Bartsch DK. Increased rate of clinically relevant pancreatic fistula after deep enucleation of small pancreatic tumors. Langenbeck’s Arch Surg. 2014;399:315–21.CrossRef
91.
Michalski CW, Liu B, Heckler M, Roth S, Sun H, Heger U, et al. Underutilization of surgery in periampullary cancer treatment. J Gastrointest Surgery. 2019;23:959–65.CrossRef
92.
Schirmacher P, Büchler MW. Ampullary adenocarcinoma–differentiation matters. BMC Cancer. 2008;8:1–2.CrossRef
93.
Wittekind C, Tannapfel A. Adenoma of the papilla and ampulla–premalignant lesions? Langenbeck’s Arch Surg. 2001;386:172–5.CrossRef
Metadata
Title
Long-Term Oncologic Outcome following Duodenum-Preserving Pancreatic Head Resection for Benign Tumors, Cystic Neoplasms, and Neuroendocrine Tumors: Systematic Review and Meta-analysis
Authors
Hans G. Beger, MD
Benjamin Mayer, PhD
Bertram Poch, MD, PD
Publication date
05-04-2024
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-024-15222-y